When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Cardiotonic agent - Wikipedia

   en.wikipedia.org/wiki/Cardiotonic_agent

   Their inotropic properties make cardiactonic agents critical in addressing inadequate perfusion, and acute heart failure conditions including cardiogenic shock, as well as for long-term management of heart failure. These conditions arise when the heart's ability to meet the body's needs is compromised.

3. PDE3 inhibitor - Wikipedia

   en.wikipedia.org/wiki/PDE3_inhibitor

   PDE3 inhibitors are indicated as inotropics for the therapy of acute heart failure if catecholamines are ineffective. [2] Well controlled studies have shown that these drugs generally increase mortality , [ 3 ] when used for the therapy of acute heart failure, so they have to be applied under close observation.

4. Amrinone - Wikipedia

   en.wikipedia.org/wiki/Amrinone

   The effects of amrinone vary widely with species and experimental condition; therefore, its inotropic effects are variable. [3] A loss in sensitivity to phosphodiesterase 3 inhibitors, including amrinone, has been observed in end stage heart failure in humans; other treatment options may be more useful for improvement in these stages. [3]

5. Inotrope - Wikipedia

   en.wikipedia.org/wiki/Inotrope

   The term inotropic state is most commonly used in reference to various drugs that affect the strength of contraction of heart muscle. However, it can also refer to pathological conditions. For example, enlarged heart muscle can increase inotropic state, whereas dead heart muscle can decrease it.

6. Milrinone - Wikipedia

   en.wikipedia.org/wiki/Milrinone

   PKA also phosphorylates components on myofilaments allowing actin and myosin to interact more easily and thus increasing contractility and the inotropic state of the heart. Milrinone allows stimulation of cardiac function independently of β-adrenergic receptors which appear to be down-regulated in those with heart failure. [13]

7. Levosimendan - Wikipedia

   en.wikipedia.org/wiki/Levosimendan

   Levosimendan / ˌ l iː v oʊ s aɪ ˈ m ɛ n d ən / is a calcium sensitizer used in the management of acutely decompensated congestive heart failure. It is marketed under the trade name Simdax (Orion Corporation). Overall the drug has a two fold mechanism of action.